Precision oncology startup 4baseCare has successfully closed its Series B funding round, securing a total of ₹128 crore, equivalent to approximately $13 million. The final phase of this round included a ₹38 crore infusion led by prominent investors growX Ventures and Infosys. This capital injection is set to accelerate the company's mission of delivering personalized cancer care through advanced genomics and artificial intelligence.
Strategic Expansion and Technological Advancement
4baseCare has outlined a clear strategy for deploying the newly acquired capital to fuel its international growth. The company intends to significantly expand its network of genomics laboratories across key emerging markets. This global push will target regions including the Middle East, Southeast Asia, Latin America, and Central Asia.
A substantial portion of the funding will also be dedicated to enhancing its proprietary AI-driven platform, OncoTwin. This platform supports clinicians by providing deeper, real-world, and clinically actionable insights for cancer treatment. The investment aims to scale its capabilities and widen its adoption among medical professionals globally.
A Mission for Inclusive Oncology
A core objective for 4baseCare is to make precision oncology more inclusive and accessible for under-represented populations. Co-founder Hitesh Goswami highlighted that most genomic datasets and clinical trials are concentrated in the US and Europe. The company is actively building solutions to address this significant data gap in emerging markets.
In India, the startup is decentralizing its testing infrastructure by establishing in-hospital genomics labs through strategic partnerships. Collaborations with institutions like Max Healthcare and AIIMS Jammu bring advanced diagnostics closer to patients. This model improves turnaround times and fosters greater research collaboration within the healthcare ecosystem.
Scaling Operations and Market Impact
Currently operating four active labs in India and conducting around 1,500 genomic tests per month, 4baseCare has ambitious growth plans. With the new funding, the company projects a significant increase in testing volume to between 8,000 and 10,000 tests monthly. This expansion is part of a broader plan to enter eight to ten new countries over the next 18 months.
The adoption of genomic testing is witnessing a notable shift beyond major metropolitan hospitals into smaller cities across India. This trend is partly driven by the company's efforts to lower costs and industry-sponsored affordability initiatives. As a result, advanced cancer diagnostics are becoming more accessible to a wider patient base.
The participation of Infosys in this funding round is viewed as a strategic move, reflecting the growing synergy between AI and healthcare. Infosys recognizes 4baseCare's potential in building AI solutions on top of valuable healthcare datasets. This aligns with the IT giant's broader exploration of enterprise solutions in the health-tech sector.
This successful Series B funding round positions 4baseCare to significantly scale its operations and impact on a global stage. By expanding its genomic lab network and enhancing its AI platform, the company is poised to advance personalized cancer care. The investment underscores the growing confidence in India's healthtech sector and its potential to innovate for diverse populations worldwide.